Olema Pharmaceuticals (NASDAQ:OLMA) Posts Quarterly Earnings Results, Beats Expectations By $0.01 EPS

Olema Pharmaceuticals (NASDAQ:OLMA) announced its quarterly earnings results on Monday. The company reported ($0.50) EPS for the quarter, beating the consensus estimate of ($0.51) by $0.01, FiscalAI reports.

Olema Pharmaceuticals Stock Performance

Shares of OLMA opened at $15.06 on Wednesday. The company has a market capitalization of $1.03 billion, a PE ratio of -8.10 and a beta of 1.92. The company has a debt-to-equity ratio of 0.01, a current ratio of 8.03 and a quick ratio of 8.03. Olema Pharmaceuticals has a one year low of $2.86 and a one year high of $36.26. The company’s fifty day moving average price is $23.81 and its 200 day moving average price is $18.73.

Insiders Place Their Bets

In other Olema Pharmaceuticals news, insider Naseem Zojwalla sold 100,000 shares of Olema Pharmaceuticals stock in a transaction that occurred on Monday, December 22nd. The stock was sold at an average price of $28.04, for a total value of $2,804,000.00. Following the transaction, the insider directly owned 53,997 shares of the company’s stock, valued at $1,514,075.88. The trade was a 64.94% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Shane William Charles Kovacs sold 100,000 shares of the company’s stock in a transaction that occurred on Thursday, January 15th. The stock was sold at an average price of $28.73, for a total value of $2,873,000.00. Following the transaction, the insider owned 139,727 shares of the company’s stock, valued at approximately $4,014,356.71. This trade represents a 41.71% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 805,501 shares of company stock valued at $23,003,832 in the last ninety days. Company insiders own 16.36% of the company’s stock.

Hedge Funds Weigh In On Olema Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the stock. AQR Capital Management LLC acquired a new position in Olema Pharmaceuticals during the 1st quarter valued at $172,000. Goldman Sachs Group Inc. grew its position in Olema Pharmaceuticals by 93.6% in the 1st quarter. Goldman Sachs Group Inc. now owns 741,329 shares of the company’s stock worth $2,787,000 after purchasing an additional 358,412 shares during the last quarter. Jane Street Group LLC grew its position in Olema Pharmaceuticals by 216.8% in the 1st quarter. Jane Street Group LLC now owns 138,552 shares of the company’s stock worth $521,000 after purchasing an additional 94,815 shares during the last quarter. Geode Capital Management LLC increased its holdings in shares of Olema Pharmaceuticals by 22.4% during the 2nd quarter. Geode Capital Management LLC now owns 1,326,123 shares of the company’s stock worth $5,650,000 after purchasing an additional 242,997 shares during the period. Finally, Creative Planning bought a new position in shares of Olema Pharmaceuticals during the 2nd quarter worth about $83,000. Institutional investors own 91.78% of the company’s stock.

More Olema Pharmaceuticals News

Here are the key news stories impacting Olema Pharmaceuticals this week:

• Positive Sentiment: Q4 earnings surprised slightly to the upside — Olema reported ($0.50) EPS vs. consensus ($0.51), which triggered positive investor reaction and immediate share strength. Press Release OLMA Stock Jumps After Q4
• Positive Sentiment: HC Wainwright raised near‑term and multi‑year EPS forecasts across 2026–2030 (slightly less negative EPS), reiterated a “Buy” rating and kept a $38 price target — signaling improving economics expectations for the company. This analyst lift supports further upside sentiment. Analyst Note
• Positive Sentiment: Citigroup raised its price target sharply (from $60 to $62) and maintains a buy view — a material, bullish institutional price-target move that can draw attention from momentum and institutional buyers. Benzinga: Citigroup
• Positive Sentiment: Large external interest tied to Olema’s breast‑cancer drug: reports note a ~$68.7M wager related to the program targeting a 2027 launch, which underscores investor confidence and potential financing/support for commercial plans. Globe and Mail: $68.7M Bet
• Positive Sentiment: Clinical visibility: Olema (via Olema Oncology) will present preclinical data for palazestrant and OP‑3136 at AACR 2026 — continued scientific disclosure can reduce clinical uncertainty and support longer‑term valuation. Business Insider: AACR Presentation
• Negative Sentiment: Guggenheim trimmed its price target (from $40 to $38) though it kept a “Buy” rating — a slight headwind as some investors may see this as less bullish relative to higher targets. Benzinga: Guggenheim

Wall Street Analysts Forecast Growth

Several research firms have commented on OLMA. Piper Sandler initiated coverage on shares of Olema Pharmaceuticals in a research report on Wednesday, January 7th. They issued an “overweight” rating and a $40.00 target price for the company. Citigroup lifted their price objective on shares of Olema Pharmaceuticals from $60.00 to $62.00 and gave the company a “buy” rating in a research note on Tuesday. HC Wainwright decreased their price objective on shares of Olema Pharmaceuticals from $45.00 to $38.00 and set a “buy” rating for the company in a report on Monday, March 9th. Guggenheim lowered their target price on shares of Olema Pharmaceuticals from $40.00 to $38.00 and set a “buy” rating on the stock in a research report on Tuesday. Finally, UBS Group began coverage on Olema Pharmaceuticals in a report on Wednesday, January 7th. They set a “buy” rating and a $45.00 target price on the stock. Ten analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $42.00.

Olema Pharmaceuticals Company Profile

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.